Aurélie Barrail-Tran

Summary

Country: France

Publications

  1. doi request reprint [Evidence-based therapeutic drug monitoring of lopinavir]
    Aurélie Barrail-Tran
    Pharmacie Clinique CHU de Bicêtre, AP HP, Le Kremlin Bicetre, France
    Therapie 66:231-8. 2011
  2. doi request reprint [Evidence-based therapeutic drug monitoring for indinavir]
    Aurélie Barrail-Tran
    Pharmacie Clinique, CHU de Bicetre, AP HP, Le Kremlin Bicetre, France
    Therapie 66:239-46. 2011
  3. pmc Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial
    A Barrail-Tran
    Hopital Bicetre, Clinical Pharmacy, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
    Antimicrob Agents Chemother 54:614-9. 2010
  4. ncbi request reprint Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
  5. pmc Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children
    Caroline Barau
    Department of Clinical Pharmacy, Assistance Publique Hopitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicetre, France
    Br J Clin Pharmacol 74:515-24. 2012
  6. pmc Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial
    Jean Jacques Parienti
    Univ Paris Diderot, Sorbonne Paris Cité, UMR 738, and INSERM, UMR 738, Paris, France
    Antimicrob Agents Chemother 57:2265-71. 2013
  7. pmc Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial
    Lauriane Goldwirt
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 55:3613-5. 2011
  8. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
  9. pmc Characterization of binding of raltegravir to plasma proteins
    Caroline Barau
    Assistance Publique, Hopitaux de Paris, Hopital Bicetre, Hôpitaux Universitaires Paris Sud, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 57:5147-50. 2013
  10. doi request reprint Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Liver Transpl 17:1152-8. 2011

Detail Information

Publications12

  1. doi request reprint [Evidence-based therapeutic drug monitoring of lopinavir]
    Aurélie Barrail-Tran
    Pharmacie Clinique CHU de Bicêtre, AP HP, Le Kremlin Bicetre, France
    Therapie 66:231-8. 2011
    ....
  2. doi request reprint [Evidence-based therapeutic drug monitoring for indinavir]
    Aurélie Barrail-Tran
    Pharmacie Clinique, CHU de Bicetre, AP HP, Le Kremlin Bicetre, France
    Therapie 66:239-46. 2011
    ....
  3. pmc Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial
    A Barrail-Tran
    Hopital Bicetre, Clinical Pharmacy, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
    Antimicrob Agents Chemother 54:614-9. 2010
    ..05). These in vivo results indicate that atazanavir pharmacokinetics is moderately influenced by its protein binding, especially to AAG, without expected clinical consequences...
  4. ncbi request reprint Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
    Aurélie Barrail-Tran
    AP HP, Hospital Bicetre, Paris, France
    AIDS 24:2581-3. 2010
    ..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
  5. pmc Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children
    Caroline Barau
    Department of Clinical Pharmacy, Assistance Publique Hopitaux de Paris, Hôpitaux Universitaires Paris Sud, Le Kremlin Bicetre, France
    Br J Clin Pharmacol 74:515-24. 2012
    ....
  6. pmc Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial
    Jean Jacques Parienti
    Univ Paris Diderot, Sorbonne Paris Cité, UMR 738, and INSERM, UMR 738, Paris, France
    Antimicrob Agents Chemother 57:2265-71. 2013
    ..Timing compliance should be supported to optimize DVS during the early phase of treatment by once-daily boosted protease inhibitor-based ART. (This study has been registered at ClinicalTrials.gov under registration no. NCT00528060.)...
  7. pmc Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial
    Lauriane Goldwirt
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 55:3613-5. 2011
    ..49, 0.76, and 0.67 and 0.82, 0.68, and 0.64 for tipranavir and darunavir, respectively. The virologic consequences of these drug interactions have yet to be determined...
  8. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  9. pmc Characterization of binding of raltegravir to plasma proteins
    Caroline Barau
    Assistance Publique, Hopitaux de Paris, Hopital Bicetre, Hôpitaux Universitaires Paris Sud, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 57:5147-50. 2013
    ..RAL did not bind to AAG but bound to nonsaturable, low-affinity albumin sites with an n (number of sites) · Ka product of 9.8 × 10(2) liters/mol. A pH increase of 0.2 U led to a 2% increase in the bound fraction. ..
  10. doi request reprint Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients
    Caroline Barau
    Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Liver Transpl 17:1152-8. 2011
    ..Furthermore, these results suggest that the coadministration of MPA with rifampin should be avoided...
  11. doi request reprint Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection
    Lauriane Goldwirt
    Pharmacie Clinique, Laboratoire de Toxicologie, CHU de Bicêtre AP HP, 78 Avenue du General LeClerc, 94270 Le Kremlin Bicetre, France
    J Chromatogr B Analyt Technol Biomed Life Sci 878:456-60. 2010
    ..8%. Application to clinical samples taken from patients treated with raltegravir indicated that the method is suitable for measuring plasma concentrations of raltegravir in pharmacokinetic studies of clinical trials...
  12. doi request reprint Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors
    Benoit Chauvin
    Clinical Pharmacy Department, Assistance Publique Hopitaux de Paris, Hopital Bicetre, Hôpitaux Universitaires Paris Sud AP HP, 78 rue du General Leclerc, 94270, Kremlin Bicetre, France
    Clin Pharmacokinet 52:815-31. 2013
    ..Effectiveness and occurrence of adverse effects should be monitored at regular time intervals. ..